Bacillus clausii + Metronidazole
ApprovedCompleted 0 views this week 0 watching⚡ Active
Interest: 43/100
43
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Irritable Bowel Syndrome
Conditions
Irritable Bowel Syndrome
Trial Timeline
Apr 1, 2006 → Jul 1, 2008
NCT ID
NCT00331994About Bacillus clausii + Metronidazole
Bacillus clausii + Metronidazole is a approved stage product being developed by Sanofi for Irritable Bowel Syndrome. The current trial status is completed. This product is registered under clinical trial identifier NCT00331994. Target conditions include Irritable Bowel Syndrome.
What happened to similar drugs?
6 of 20 similar drugs in Irritable Bowel Syndrome were approved
Approved (6) Terminated (1) Active (14)
Hype Score Breakdown
Clinical
20
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00331994 | Approved | Completed |
Competing Products
20 competing products in Irritable Bowel Syndrome
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| linaclotide + placebo | Astellas Pharma | Phase 2 | 35 |
| YM060 + Placebo | Astellas Pharma | Phase 3 | 40 |
| Ramosetron + Placebo | Astellas Pharma | Approved | 43 |
| Ramosetron + Placebo | Astellas Pharma | Approved | 43 |
| YM060 | Astellas Pharma | Phase 3 | 40 |
| YM060 + placebo | Astellas Pharma | Phase 2 | 35 |
| YM060 | Astellas Pharma | Phase 3 | 40 |
| linaclotide + Placebo | Astellas Pharma | Phase 3 | 40 |
| Ramosetron | Astellas Pharma | Pre-clinical | 26 |
| YM060 | Astellas Pharma | Phase 2 | 35 |
| ONO-2952 + Placebo comparator | Ono Pharmaceutical | Phase 2 | 27 |
| ONO-2952 + ONO-2952 Matching Placebo | Ono Pharmaceutical | Phase 2 | 35 |
| duloxetine | Eli Lilly | Approved | 43 |
| Irritable Bowel Syndrome with Constipation (IBS-C) participants (LIN-MD-63 and LIN-MD-64 completers) + Functional Constipation (FC) participants (LIN-MD-62 and LIN-MD-64 completers) | AbbVie | Phase 3 | 40 |
| 25mg Eluxadoline + 100mg Eluxadoline | AbbVie | Phase 3 | 47 |
| Eluxadoline + Placebo | AbbVie | Phase 2 | 42 |
| Placebo + Linaclotide | AstraZeneca | Phase 3 | 40 |
| Tegaserod | Novartis | Pre-clinical | 26 |
| DNK333 | Novartis | Phase 2 | 35 |
| SMS995 + Placebo | Novartis | Phase 1 | 29 |